December 16, 2016 08:21 AM EST
Pharma

In a first, As­traZeneca gains rights to an an­ti­sense KRAS drug in $165M Io­n­is deal

Arsalan Arif

Founder

As­traZeneca is hand­ing over $28 mil­lion to Io­n­is in ex­change for rights to de­vel­op one of its ear­ly-stage can­cer drugs. The phar­ma gi­ant has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

US drugs re­ly heav­i­ly on in­gre­di­ents made over­seas, new re­port shows

Biotech seed rounds sink to low­est lev­el in years as in­dus­try slump drags on

Phar­ma's wins and loss­es in Trump's sprawl­ing ex­ec­u­tive or­der on drug prices

Eli Lil­ly re­ports first Phase 3 da­ta for oral GLP-1, post­ing a win in di­a­betes

Ex­clu­sive: VelaV­i­go inks an­oth­er US biotech deal as Chi­na drug de­vel­op­ment scene booms

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times